Less-Known Phosphodiesterase Type 5 Inhibitors – New Solutions for the Therapy of Erectile Dysfunction
Keywords:
phosphodiesterase type 5 inhibitors, erectile dysfunction, lodenafil, mirodenafil, yokenafil, SLx-2101 and simmerafilAbstract
Erectile dysfunction (ED) is a serious health problem that directly affects quality of males’ life. In the drug treatment of ED, a group of phosphodiesterase type 5 inhibitors plays an important role (PDE-5), which is the first line of treatment for ED. This article presents the currently available data regarding the parameters of pharmacokinetics, pharmacodynamics and possible adverse events of PDE-5 inhibitors that are not so widely known or are at various stages of clinical trials. Less-known PDE-5 inhibitors, which are presented in the article, include lodenafil, mirodenafil, yokenafil, SLx-2101 and simmerafil.
References
Wiley K. Erectile dysfunction. Adv Psychosom Med. 2008;29:33-49.
Chaly M.E., Akhvlediani N.D., Kharchilava R.R. Erectile disfunction. Russian clinical guidelines. Urology. 2017; 2 (Appendix 2): 20-30 (in Russian).
Ding R.K., Liu T.F. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clean North Am. 2005;32(4):379-95.
Cho MC, Paik JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. May 14, 2014; 10: 341-54.
Pastushak AV. Current diagnosis and treatment of erectile dysfunction. Curr Sex Health Rep. 2014;6(3):164-176.
Liu T.F. Erectile disfunction. N Engl J Med. June 15, 2000; 342(24):1802-13.
McVary K.T. Erectile disfunction. New English J. Med. 2007; 357:2472-2481.
Yafi F.A., Jenkins L., Albersen M., Corona G., Isidori A.M., Goldfarb S., Maggi M., Nelson S.J., Parish S., Salonia A., Tan R., Mulhall JP, Hellstrom WJ. Erectile disfunction. Primers Nat Rev Dis. February 4, 2016; 2:16003.
Perelman MA. The influence of relationship variables on the etiology, diagnosis and treatment of erectile dysfunction. Adv Primary Care Med: Clin Update. 2007;3:3-6.
Porst H, Burnett A, Brock G, Ganem H, Giuliano F, Glina S, et al. SOP for conservative (medical and mechanical) treatment of erectile dysfunction. Jay Sex Med. 2013;10(1):130–71.
Tsertsvadze A., Fink H.A., Yazdi F., McDonald R., Bella A.J., Ansari M.T. et al. Oral phosphodiesterase-5 inhibitors and hormonal treatment of erectile dysfunction: a systematic review and meta-analysis. Ann, intern, med. 2009;151(9):650-61.
Gafarov R.R., Shodmonova Z.R., Allazov S.A., Khamroev G.A., Tukhtaev F.M. Phosphodiesterase type 5 inhibitors are the first line of treatment for erectile dysfunction. Achievements of science and education. 2020;5(59):103-108 (in Russian).
Glina S, Toscano I, Gomacki S, de Goes PM, Junior AN, Claro JF, Pagani E. Efficacy and tolerability of oral lodenafil carbonate for erectile dysfunction: a phase II clinical trial . Jay Sex Med. 2009;6(2):553-7.
Glina S., Fonseca G.N., Bertero E.B. et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010;7(5):1928-36.
Pick TK, Yafi FA, Sangkum P, Hellstrom WJ. New drugs for the treatment of erectile dysfunction. Expert opinion on emergency medications. 2015;20(2):263-75.
Park HJ, Moon KH, Lee SW, Lee WK, Kam SK, Lee JH, Park NC. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World Jay Men's Health. 2014;32(1):18-27.
Paik JS, Ahn TY, Choi HK. et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for the treatment of erectile dysfunction. J Sex Med 2008;5(11):2672-80.
Lee J.I., Cho S.I., Oh S.I. et al. Efficacy and safety of combination therapy with mirodenafil and an alpha1-blocker for lower urinary tract symptoms caused by benign prostatic hyperplasia, accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res 2011;23(6):249-56.
Wang K, Ding J, Li H, Guo W, Zhu X, Su Y, Sun L, Zhou H, Ding L. Effects of itraconazole and rifampicin on the pharmacokinetics and safety of ekenafil, a novel phosphodiesterase type 5 inhibitor, in healthy subjects. Chinese items. Eur J Pharm Sci. 2022; 1(175):106213.
Liang B, Wang J, Bai N, Chi Y, Wang R, Cai Y. Safety, tolerability, and pharmacokinetics of single and multiple escalating oral doses of ekenafil hydrochloride, a phosphodiesterase type 5 inhibitor, in healthy Chinese male volunteers. Clin Pharmacol Drug Dev. 2022;11(10):1184-1190.
Sweetnam P, Campbell S, Grogan M, et al. SLx-2101, a novel long-acting phosphodiesterase-5 (PDE5) inhibitor for erectile dysfunction: in vivo and in vitro studies [abstract no. 51]. Jay Sex Med, 2006; 3 Add. 1:30 60.
Prince WT, Campbell AC, Tong W, et al. SLx-2101, a novel long-acting PDE5 inhibitor: preliminary safety, tolerability, pharmacokinetics, and effects on endothelial function in healthy subjects. Jay Sex Med, 2006; 3 Add. 1:29-30.
Hatzimouratidis K., Hatzichristou D.G. A look into the future of erectile dysfunction treatment. Drugs. 2008;68(2):231-50.
Qian H, Chen Q, Liang L, Zou Y, Pu H, Xin L, Song R, Li T, Zhu H, Wang Y, Tian G, Shen J, Jiang X, Yu X, Wang Zi, Jia J. Phase Ya studying the safety, tolerability, and pharmacokinetics of TPN171H, a novel phosphodiesterase type 5 inhibitor, in healthy subjects. The drug Des Devel Ter. 2021; 6(15):2947–2959.
Yafi F.A., Sharlip I.D., Becher E.F. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Sex Med Ed. 2018;6(2):242-252.
Shodmonova Z.R., Gafarov R.R., Allazov S.A., Giyasov S.I. Phosphodesterase type 5 inhibitors - clinical efficiency and role in therapy for erectile dysfunction // Urologiia. - 2021. - N. 2. - P. 135-140. doi: 10.18565/urology.2021.2.135-140.
Гафаров Рушен Рефатович, Шодмонова Зебунисо Рахимовна, Аллазов Салах Аллазович, Хамроев Гулом Абдуганиевич, Тухтаев Фирдавс Мухиддинович Ингибиторы фосфодиэстеразы 5 типа – первая линия терапии эректильной дисфункции // Достижения науки и образования. 2020. №5 (59).
РР Гафаров, НА Бобокулов, ХФ Файзиев Ингибиторы фосфодиэстеразы 5 типа–побочные эффекты и нежелательные явления, связанные с применением. European journal of molecular medicine. 2024; (4)1: 40-45.
